Infectious Disease Molecular Diagnostics Market Dynamics and Competitive Landscape By 2028

Infectious Disease Molecular Diagnostics Industry Overview

The global infectious disease molecular diagnostics market size was valued at USD 32.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.0% from 2020 to 2028.

The growth can be attributed to the growing use of molecular diagnostics in infection detection, the rising geriatric population, and the increasing demand for point-of-care molecular diagnostics. The outbreak of COVID-19 is anticipated to act as a key driver.

Gather more insights about the market drivers, restrains and growth of the Global Infectious Disease Molecular Diagnostics Market

The global geriatric population is increasing. Over 727.0 million people globally were categorized in the age group 65 and above. The geriatric population is more susceptible to COVID-19 owing to multimorbidity, decreased immune function, and physiological changes associated with aging. According to CDC in 2021, 80% of COVID-19 related deaths were among people aged over 65. Thus, this group has to be tested continuously to avoid severe infections, which creates growth opportunities for molecular diagnostic tests in regions such as Russia, Japan, and the U.S. that have the highest elderly people globally.

The infectious disease molecular diagnostics test menus cannot afford to be static or superficial due to the diverse nature of infectious diseases and the building resistance of causative agents. For instance, the coronavirus outbreak in China was declared a global health emergency by the WHO in January 2020. RT-PCRs and sequencing tools were used in the identification and characterization of the virus.

An increase in external funding to conduct clinical studies in infectious disease molecular diagnostics is expected to drive the market. Funding plays a significant role in the product development process. For instance, in October 2019, Sense Biodetection Limited received an investment of USD 16.85 million for POC molecular diagnostic development with an initial focus on infectious diseases such as influenza diagnostics.

Browse through Grand View Research’s Clinical Diagnostics Industry Research Reports.

• Point-of-Care Molecular Diagnostics Market – The global point-of-care molecular diagnostics market size was valued at USD 1.72 billion in 2018 and is anticipated to expand at a CAGR of 14.4% over the forecast period.
• Infectious Disease In Vitro Diagnostics Market – The global infectious disease in vitro diagnostics market size was estimated at USD 113.61 billion in 2021 and is expected to decline at a compound annual growth rate (CAGR) of – 7.4% from 2022 to 2030.

Market Share Insights

• February 2021: BD announced the launch of its Influenza A+B and SARS-CoV-2 in a single test with a CE mark. The product received a EUA from FDA in the same month.
• December 2020: Bruker Corporation announced the launch of a winter four-plex PCR panel called FluoroType that can detect RSV, Flu, and SARS-CoV-2.

Key Companies profiled:

Some prominent players in the global infectious disease molecular diagnostics market include

• Abbott
• Danaher Corporation
• bioMérieux SA
• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Hologic, Inc. (Gen-Probe)
• Illumina, Inc.
• Grifols S.A.
• Qiagen
• Siemens Healthineers AG
• Sysmex Corporation

Order a free sample PDF of the Infectious Disease Molecular Diagnostics Market Intelligence Study, published by Grand View Research.